loading
前日終値:
$2.92
開ける:
$2.9
24時間の取引高:
59,268
Relative Volume:
0.40
時価総額:
$2.84M
収益:
-
当期純損益:
$-15.52M
株価収益率:
-0.1635
EPS:
-18.58
ネットキャッシュフロー:
$-16.61M
1週間 パフォーマンス:
-5.23%
1か月 パフォーマンス:
+12.50%
6か月 パフォーマンス:
-77.19%
1年 パフォーマンス:
-91.05%
1日の値動き範囲:
Value
$2.80
$3.1096
1週間の範囲:
Value
$2.76
$3.3223
52週間の値動き範囲:
Value
$2.36
$60.80

Revelation Biosciences Inc Stock (REVB) Company Profile

Name
名前
Revelation Biosciences Inc
Name
セクター
Healthcare (1153)
Name
電話
650-800-3717
Name
住所
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Name
職員
9
Name
Twitter
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
REVB's Discussions on Twitter

REVB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
REVB
Revelation Biosciences Inc
2.9693 2.84M 0 -15.52M -16.61M -18.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.66 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.82 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
634.11 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
258.70 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
248.15 24.70B 3.81B -644.79M -669.77M -6.24

Revelation Biosciences Inc (REVB) 最新ニュース

pulisher
Apr 10, 2025

Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey

Apr 10, 2025
pulisher
Mar 21, 2025

Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World

Mar 21, 2025
pulisher
Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire

Mar 17, 2025
pulisher
Mar 13, 2025

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire

Mar 13, 2025
pulisher
Mar 10, 2025

What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World

Mar 10, 2025
pulisher
Mar 07, 2025

REVB: 2025 Is the Year for Measurable Progress - Research Tree

Mar 07, 2025
pulisher
Mar 06, 2025

Revelation Biosciences Inc. (REVB) reports earnings - Quartz

Mar 06, 2025
pulisher
Mar 06, 2025

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ

Mar 06, 2025
pulisher
Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks

Feb 26, 2025
pulisher
Feb 26, 2025

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire

Feb 26, 2025
pulisher
Feb 26, 2025

Artificial Intelligence (AI) News Live Feed - StockTitan

Feb 26, 2025
pulisher
Feb 24, 2025

Revelation Biosciences gets continued listing approval from Nasdaq - MSN

Feb 24, 2025
pulisher
Feb 24, 2025

Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire

Feb 24, 2025
pulisher
Feb 24, 2025

Can This Biotech's New Kidney Disease Trial Transform CKD Treatment? Key Details - Stock Titan

Feb 24, 2025
pulisher
Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025
pulisher
Feb 11, 2025

Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR

Feb 11, 2025
pulisher
Feb 03, 2025

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

Feb 03, 2025
pulisher
Jan 30, 2025

Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL

Jan 30, 2025
pulisher
Jan 30, 2025

Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR

Jan 30, 2025
pulisher
Jan 30, 2025

Revelation Biosciences stock hits 52-week low at $0.28 - MSN

Jan 30, 2025
pulisher
Jan 29, 2025

REVB Start 1B Trial and Announces Split - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree

Jan 29, 2025
pulisher
Jan 28, 2025

Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn

Jan 28, 2025
pulisher
Jan 28, 2025

Revelation Biosciences Inc (REVB) Has Strong Growth Prospects Through 2025 - Marketing Sentinel

Jan 28, 2025
pulisher
Jan 27, 2025

Anthem man charged with insider trading - Foothills Focus

Jan 27, 2025
pulisher
Jan 24, 2025

Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada

Jan 24, 2025
pulisher
Jan 24, 2025

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace

Jan 24, 2025
pulisher
Jan 24, 2025

Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN

Jan 24, 2025
pulisher
Jan 24, 2025

Revelation Bio Announces 1:16 Reverse Split, Advances CKD Drug Trial to Phase 1b - Stock Titan

Jan 24, 2025
pulisher
Jan 21, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com

Jan 21, 2025
pulisher
Jan 21, 2025

Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - Stock Titan

Jan 21, 2025
pulisher
Jan 20, 2025

Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak

Jan 20, 2025
pulisher
Jan 19, 2025

Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN

Jan 19, 2025

Revelation Biosciences Inc (REVB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
大文字化:     |  ボリューム (24 時間):